How CBG can help you

Cannabigerol (CBG) is a non-psychoactive cannabinoid that is found in the cannabis plant. Unlike THC, which is the primary psychoactive compound in cannabis, CBG does not produce a “high” effect when consumed. Instead, CBG has been found to have a range of potential therapeutic benefits, including anti-inflammatory, neuroprotective, and pain-relieving effects (Russo, 2011).

CBG can be obtained from cannabis plants through a process called extraction. This involves using a solvent, such as ethanol or CO2, to extract the CBG from the plant material. Once the CBG has been extracted, it can be further purified and processed into various forms, such as oils, capsules, or topical creams.

Research on CBG is still in its early stages, but there is growing evidence to suggest that it may have a range of potential health benefits. For example, CBG has been found to have anti-inflammatory effects, which could make it useful in the treatment of conditions such as inflammatory bowel disease and arthritis (Russo, 2011). CBG also appears to have neuroprotective effects, which could make it useful in the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s (Valdeolivas et al., 2015).

CBG may also have some unique properties that make it useful in the production of other cannabis products. For example, CBG has been found to have antibacterial properties, which could make it useful in the production of cannabis-based products for skin care and other topical applications (Appendino et al., 2008).

In addition to the benefits mentioned earlier, there are several other potential therapeutic benefits of CBG that have been discovered through preliminary research. For example, CBG has been found to have analgesic (pain-relieving) effects, which could make it useful in the treatment of chronic pain conditions (Gugliandolo et al., 2020). CBG has also been found to have anti-tumor effects, which could make it a potential treatment for certain types of cancer (Blasco-Benito et al., 2019).

Furthermore, CBG has been found to have potential antidepressant effects, making it a potential treatment for depression and other mood disorders (Brierley et al., 2016). CBG has also been found to have potential anti-convulsant effects, making it a potential treatment for conditions such as epilepsy and seizures (Ternianov et al., 2020).

Finally, CBG has been found to have potential anti-glaucoma effects, making it a potential treatment for this eye condition (Colasanti et al., 2007). In addition, CBG has been found to have antioxidant properties, which could make it useful in protecting against oxidative stress and certain chronic diseases (Pagano et al., 2020).

Overall, while research on CBG is still in its early stages, there is growing evidence to suggest that this non-psychoactive cannabinoid may have a range of potential therapeutic and practical applications. Further research is needed to fully understand the potential benefits and limitations of CBG, but it is clear that this compound is an important area of study for the future of cannabis research and development.

References: 

Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., … & Antibacterial cannabinoids from Cannabis sativa: a structure− activity study. Journal of natural products, 71(8), 1427-1430.

Blasco-Benito, S., Seijo-Vila, M., Caro-Villalobos, M., Tundidor, I., Andradas, C., García-Taboada, E., … & Sánchez, C. (2019). Appraising the “entourage effect”: antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochemical pharmacology, 157, 285-293.

Brierley, D. I., Samuels, J., Duncan, M., Whalley, B. J., & Williams, C. M. (2016). Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology, 233(19-20), 3603-3613.

Colasanti, B. K., Craig, C. R., & Allara, R. D. (2007). Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Experimental eye research, 85(3), 417-422.

Gugliandolo, A., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2020). In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid. International journal of molecular sciences, 21(23), 8692.

Pagano, E., Montanaro, V., Di Girolamo, A., Pistone, A., Altieri, V., & Zjawiony, J. K. (2020). Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Frontiers in pharmacology, 11, 573911.

Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British journal of pharmacology, 163(7), 1344-1364.

Ternianov, A., Pérez-Rosés, R., Ojeda-Sánchez, P., Papaseit, E., Torrens, M., Farré, M., & de la Torre

Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015). Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1), 185-199.